



## Etesevimab and Bamlanivimab

Revised: November 15, 2023.

CASRN: 2423948-94-9; 2423943-37-5

### Drug Levels and Effects

#### Summary of Use during Lactation

The distribution of etesevimab and bamlanivimab was stopped in June of 2021 because of a lack of efficacy against COVID-19 variants. Etesevimab and bamlanivimab are monoclonal antibodies directed against the SARS-CoV-2 virus that causes COVID-19. No information is available on their clinical use during breastfeeding. Because etesevimab and bamlanivimab are large protein molecules with molecular weights of 146,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2]

#### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

#### Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

#### Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

#### Alternate Drugs to Consider

Nirmatrelvir, Remdesevir

---

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## References

1. Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. *Reprod Breed* 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003
2. Anderson PO. Monoclonal antibodies during breastfeeding. *Breastfeed Med* 2021;16:591-3. PubMed PMID: 33956488.

## Substance Identification

### Substance Name

Etesevimab

### CAS Registry Number

2423948-94-9

### Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Monoclonal

Antibodies, Viral

Antiviral Agents